<em>IL-23p19−/−em>, <em>IL-17A/F−/−em>, <em>CCR2−/−em>, and wild-type (WT) mice were intra-hepatically infected with <em>E. histolyticaem> trophozoites and disease onset and recovery were analyzed by magnetic resonance imaging. Liver-specific gene and protein expression during infection was examined by qPCR, microarray, FACS analysis and immunohistochemistry. Immuno-depletion and substitution experiments were performed in <em>IL-23p19−/−em> and WT mice to investigate the role of IL-13 in disease outcome.
Liver damage in infected <em>IL-23p19−/−em>, <em>IL-17A/F−/−em>, and <em>CCR2−/−em> mice was strongly attenuated compared with that in WT mice. <em>IL-23p19−/−em> mice showed reduced accumulation of <em>IL-17em> and <em>CCL2em> mRNA and proteins. Increased numbers of IL-13-producing CD11b+Ly6Clo monocytes were associated with disease attenuation in <em>IL-23p19−/−em> mice. Immuno-depletion of IL-13 in <em>IL-23p19−/−em> mice reversed this attenuation and treatment of infected WT mice with an IL-13/anti-IL-13-mAb complex supported liver recovery.
The IL-23/IL-17 axis plays a critical role in the immunopathology of hepatic amebiasis. IL-13 secreted by CD11b+Ly6Clo monocytes may be associated with recovery from liver damage. An IL-13/anti-IL13-mAb complex mimics this function, suggesting a novel therapeutic option to support tissue healing after liver damage.